皮下转移性黑色素瘤概述
Overview of Subcutaneous Metastatic Melanoma.
作者信息
Mozzillo Nicola
机构信息
Department of Melanoma and Soft Tissue, Istituto Nazionale dei Tumori, 80131 Naples, Italy.
出版信息
Cancers (Basel). 2021 Apr 25;13(9):2063. doi: 10.3390/cancers13092063.
Abstract
Melanoma is among the most common primary solid tumors with cutaneous and subcutaneous metastasis [...].
摘要
黑色素瘤是最常见的原发性实体瘤之一，可发生皮肤和皮下转移[...]。
相似文献
1
Overview of Subcutaneous Metastatic Melanoma.皮下转移性黑色素瘤概述
Cancers (Basel). 2021 Apr 25;13(9):2063. doi: 10.3390/cancers13092063.
2
Cutaneous metastases of malignant melanoma: a clinicopathologic study of 192 cases with emphasis on the morphologic spectrum.恶性黑色素瘤的皮肤转移：192例临床病理研究，重点关注形态学谱
Am J Dermatopathol. 2010 Apr;32(2):129-36. doi: 10.1097/DAD.0b013e3181b34a19.
3
Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: recommendations for initial staging examinations.原发灶不明的转移性黑色素瘤与区域转移性黑色素瘤的预后相似：初始分期检查建议
Cancer. 1997 Jul 1;80(1):60-5. doi: 10.1002/(sici)1097-0142(19970701)80:1<60::aid-cncr8>3.0.co;2-j.
4
Melanocytic schwannoma of the cutaneous and subcutaneous tissues: three cases and a review of the literature.皮肤和皮下组织的黑素细胞性神经鞘瘤：三例报告并文献复习
Melanoma Res. 2008 Dec;18(6):438-42. doi: 10.1097/CMR.0b013e32831270d7.
5
Metastatic pathways and time courses in the orderly progression of cutaneous melanoma.皮肤黑色素瘤有序进展中的转移途径和时间进程。
Br J Dermatol. 2002 Jul;147(1):62-70. doi: 10.1046/j.1365-2133.2002.04867.x.
6
Mitotic rate and subcutaneous involvement are prognostic factors for survival after recurrence in patients with only locoregional skin metastasis as the first site of recurrence from cutaneous melanoma.有丝分裂率和皮下侵犯是皮肤黑色素瘤患者仅有局部皮肤转移复发后生存的预后因素。
J Eur Acad Dermatol Venereol. 2013 Apr;27(4):436-41. doi: 10.1111/j.1468-3083.2012.04454.x. Epub 2012 Feb 4.
7
Prognostic implications of p53 overexpression in cutaneous melanoma from sun-exposed and nonexposed sites.p53过表达在暴露于阳光部位和非暴露部位皮肤黑色素瘤中的预后意义。
Cancer. 1998 Jan 15;82(2):309-16. doi: 10.1002/(sici)1097-0142(19980115)82:2<317::aid-cncr10>3.0.co;2-1.
8
Glypican 6 is a putative biomarker for metastatic progression of cutaneous melanoma.Glypican 6 是皮肤黑色素瘤转移进展的一个有潜力的生物标志物。
PLoS One. 2019 Jun 14;14(6):e0218067. doi: 10.1371/journal.pone.0218067. eCollection 2019.
9
The developmentally regulated neural crest-associated glycotope HNK-1 predicts metastasis in cutaneous malignant melanoma.发育调控的神经嵴相关糖表位HNK-1可预测皮肤恶性黑色素瘤的转移。
J Pathol. 2004 Aug;203(4):933-9. doi: 10.1002/path.1595.
10
Patients with melanoma metastases at cutaneous and subcutaneous sites are highly susceptible to interleukin-2-based therapy.皮肤和皮下部位发生黑色素瘤转移的患者对基于白细胞介素-2的治疗高度敏感。
J Immunother. 2001 Jan-Feb;24(1):88-90. doi: 10.1097/00002371-200101000-00010.
本文引用的文献
1
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.未经治 BRAF 野生型晚期黑色素瘤患者接受纳武利尤单抗治疗的生存结局：一项随机 3 期试验的 3 年随访。
JAMA Oncol. 2019 Feb 1;5(2):187-194. doi: 10.1001/jamaoncol.2018.4514.
2
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.外泌体 PD-L1 有助于免疫抑制，并与抗 PD-1 反应相关。
Nature. 2018 Aug;560(7718):382-386. doi: 10.1038/s41586-018-0392-8. Epub 2018 Aug 8.
3
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.帕博利珠单抗辅助治疗与安慰剂对照用于 III 期黑色素瘤完全切除术后患者的随机、双盲、III 期临床试验
N Engl J Med. 2018 May 10;378(19):1789-1801. doi: 10.1056/NEJMoa1802357. Epub 2018 Apr 15.
4
Adjuvant vemurafenib in resected, BRAF mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.辅助维莫非尼治疗 BRAF 突变阳性黑色素瘤（BRIM8）：一项随机、双盲、安慰剂对照、多中心、III 期临床试验。
Lancet Oncol. 2018 Apr;19(4):510-520. doi: 10.1016/S1470-2045(18)30106-2. Epub 2018 Feb 21.
5
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.新辅助加辅助达拉非尼和曲美替尼与高危可切除黑色素瘤患者的标准治疗相比：一项单中心、开放标签、随机、2 期临床试验。
Lancet Oncol. 2018 Feb;19(2):181-193. doi: 10.1016/S1470-2045(18)30015-9. Epub 2018 Jan 18.
6
Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases.远处转移黑色素瘤行完全手术切除和辅助免疫治疗后的长期生存。
Ann Surg Oncol. 2017 Dec;24(13):3991-4000. doi: 10.1245/s10434-017-6072-3. Epub 2017 Oct 10.
7
Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis.电化学疗法治疗皮肤转移性黑色素瘤患者的持久应答。
BMC Cancer. 2013 Dec 1;13:564. doi: 10.1186/1471-2407-13-564.
8
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.MEK162 治疗携带 NRAS 或 Val600 BRAF 突变的晚期黑色素瘤患者：一项非随机、开放标签的 2 期研究。
Lancet Oncol. 2013 Mar;14(3):249-56. doi: 10.1016/S1470-2045(13)70024-X. Epub 2013 Feb 13.
9
Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma.使用新辅助电化学疗法治疗黑色素瘤患者面颊部的一个大转移病灶。
J Transl Med. 2012 Jun 22;10:131. doi: 10.1186/1479-5876-10-131.
10
Predicting outcomes in metastatic melanoma.预测转移性黑色素瘤的预后
J Clin Oncol. 2008 Jan 10;26(2):168-9. doi: 10.1200/JCO.2007.13.8123.
Zotero 插件